cyrilzakka/clinical-trials huggingface dataset:
Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer Patients

The goal of this observational study is to explore the influence and predictive significance of nutritional risk indicators and inflammatory indicators on postoperative complications and prognosis of patients with epithelial ovarian cancer (EOC). The main question it aims to answer is:

Can preoperative nutritional risk and inflammatory indexes predict postoperative complications? Do preoperative nutritional risk and inflammatory indexes better predict the prognosis of patients with epithelial ovarian cancer? Which index is the best predictor of postoperative complications or prognosis for patients?


Eligibility Criteria:
Inclusion Criteria:

1. histologically confirmed primary epithelial ovarian, peritoneal, and fallopian tube cancers.
2. patients received comprehensive staged surgery or debulking surgery.
3. available data of laboratory examination within 7 days before the surgery.

Exclusion Criteria:

1. borderline ovarian tumor.
2. receipt of neoadjuvant chemotherapy.
3. presence of other conditions influencing laboratory data, like hepatitis, kidney disease, autoimmune diseases, infectious diseases, blood disease, etc.
4. concurrent cancer in other organs.
5. absence of surgery or biopsy only.
6. multiple staged surgeries.
Expressive Writing for the Management of Stress in Cancer Survivors

This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times.

PRIMARY OBJECTIVES:

I. To evaluate the feasibility of the virtual study for cancer survivors. II. To preliminarily assess the impact of the intervention for cancer survivors.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (INTERVENTION): Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief positive messages and write essays about their experiences over 30 minutes (non-stop) once weekly (QW) for 3 weeks.

ARM II (CONTROL): Patients complete questionnaires over 30 minutes about their mood, health, and income at baseline, and 1, 3, and 6 months. Patients also read brief neutral messages and write essays about neutral topics over 30 minutes (non-stop) QW for 3 weeks.

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years old
* Have a diagnosis of cancer within the past 3 years
* Are able to speak and read in English
* Have access to a computer or smart phone with internet connection
* All disease sites and all cancer stages are eligible for enrollment

Exclusion Criteria:

* Inability to provide informed consent
* Non-English speakers will be excluded because this is a feasibility study that will enroll only a limited number of participants
Survival Rate of 2 Implant-supported Short-span Fixed Partial Dentures

Implant supported superstructure is necessary for long term success and durability of the implant itself in terms of stresses distribution and fracture strength capability.1 Stresses falling on an implant are too much greater than those applied on a tooth structure with a periodontal ligament offering a degree of elasticity. The important mechanical and physical properties of materials used for the fabrication of dental prostheses include adequate flexural and tensile strength and modulus of elasticity, maximum fracture resistance, optimal bond strength and adequate polishability.

The relationship between implants/ prosthetic components and the surrounding soft and hard tissues is complex and determines the final clinical result. For example, crestal bone resorption, frequently observed following implant placement or following loading, may be related to factors such as the establishment of the biologic width, the macro design of the cervical area of the implant and possible surface treatments, the type of implant/abutment connection, the positioning of the implant in relation to the bone crest, the width of the alveolar ridge, the distance between contiguous implants, the surgical procedure, and the effects of overloading and peri-implantitis. The establishment of the biologic width perse is related to a series of events that results in remodeling of the bone that surrounds the implants, a fact that has been observed by histomorphometry and radiographic analysis.

The aim of the present study was to compare and evaluate the survival rate and crestal bone levels around immediately placed implants in the esthetic zone with delayed, progressive, or immediately placed.

Eligibility Criteria:
Inclusion Criteria:

* fully dentulous people over 25 who complained of the mobility of 4 mandibular incisor teeth, or partially dentulous people who missed 2 mandibular central incisor teeth and had periodontally affected the neighboring lateral incisor teeth.
* These individuals were subsequently treated with 2 implants supporting FPDs and following a delayed, progressive, or immediate loading protocol
* Class 0 or 1 bone defects after tooth extraction, were only included in the study
* The medical records included data regarding implant type, width, and length, surgical procedure, annual hygienist treatments, radiographs, and implant insertion date

Exclusion Criteria:

* had less than 1 years of follow-up, had incomplete restorative or surgical data, had non-diagnostic radiographs, had more or less than 4 unit fixed partial denture
* patients did not present for annual follow-up visits to evaluate oral hygiene measures or treat mechanical or technical complications.
* Individuals with bone defects class 2, 3, 4, or 5 after mandibular lateral incisor tooth extraction were also excluded.
Enteroendocrine Cells Before and After Sleeve Gastrectomy

Morbidly obese patients exhibit impaired secretion of satiation hormones which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls.

Morbidly obese patients exhibit impaired secretion of satiation hormones cholecystokinin (CCK), glucagon-like peptide 1 (GLP-1) and peptide YY (PYY), which may contribute to the development of obesity. Bariatric surgery is associated with weight loss and dramatic increase in the secretion of satiation hormones, but the underlying mechanism remains unknown. A better understanding of mechanisms involved will assist in development of non-invasive therapeutic strategies. The investigator's goal is therefore to examine patients before and after sleeve gastrectomy and compare findings to lean controls. Gastric and intestinal mucosa will be collected by endoscopy from morbidly obese subjects before and 3 months after sleeve gastrectomy. In Addition, lean controls will be examined. Expression of various gut peptides will be assessed by immunohistochemistry and quantitative polymerase chain reaction (PCR).

Eligibility Criteria:
Inclusion Criteria:

Morbidly obese patients scheduled for sleeve gastrectomy

* BMI \> 35 kg/m2
* Age: \> 18-65 years Lean, healthy controls
* BMI \> 18 and \< 28kg/m2
* Age: \>18-40 years

Exclusion Criteria:

* Bleeding diathesis
* Previous surgery on the gastrointestinal tract (appendectomy acceptable)
A Prospective Randomized Study for Comparison of Y-Composite Grafts

The purpose of this study is to compare early and 1-year graft patency rates of saphenous vein composite grafts with those of right internal thoracic artery composite graft and mid-term clinical outcomes in patients who undergo off-pump coronary artery bypass grafting(OPCAB). We also evaluate microscopic findings of saphenous vein graft harvested no touch technique and used as composite graft.

The SAVERITA trial was designed as a randomized, controlled trial to recruit 224 patients who undergo off-pump coronary artery bypass using Y-composite graft based on the left internal thoracic artery. Patients were randomized by use of a randomization table. Composite conduit was made using saphenous vein or right internal thoracic artery according to the randomization result. The primary end point is to evaluate early and 1-year postoperative graft patency. The secondary end points are overall survival, freedom from cardiac death and freedom from MACCE(major adverse cardiac or cerebrovascular events). In saphenous vein group, 20 remnant saphenous vein specimen was evaluated histologically to compare the difference between composite grafted vein and manually dilated saphenous vein.

Eligibility Criteria:
Inclusion Criteria:

* age equal or more than 40
* age equal or less than 75
* patients who agree to the enrollment

Exclusion Criteria:

* Patients with heart failure (left ventricular ejection fraction \< 25%)
* patients who have intractable ventricular arrhythmia
* patients who has been treated for cancer
* patients who has infectious disease
* patients who are planned to undergo combined cardiac surgery
* patients who has medical co-morbidity with expected survival less than 1 year
* patients who has a problem using right internal thoracic artery or saphenous vein
* patients with a history of previous cardiac surgery
* Patients with chronic renal failure
* patients who undergo emergency operation
A Trial of Behavioral Economic Interventions Among Food Pantry Clients

Obesity, unhealthy dietary habits, and food insecurity are major public health concerns, especially affecting individuals living in poverty. Food pantries, which provide free food to those in need, are increasingly interested in promoting healthy choices, but few rigorous studies have tested healthy eating interventions in food pantry settings. The overall objective of this proposal is to conduct a randomized-controlled trial among 500 regular food pantry clients to compare the influence of a behavioral economic intervention to promote healthier food choices delivered via a web-based ordering platform to usual care (control group).

The primary objective of this proposal is to evaluate the influence of a web-based behavioral economic intervention compared to a control group on the following outcomes among food pantry clients: 1) Nutritional quality of food chosen at the pantry using food transaction data; 2) Fruit and vegetable intake measured by biomarkers and food frequency questionnaires; 3) Objectively measured biomarkers of health. The web-based behavioral economic intervention will include the following modifications to the online shopping platform: 1) Healthy food shopping cart defaults, 2) healthy placement choice architecture, 3) traffic light nutrition labels, 4) social norms messaging, and 5) healthy swaps. Food transaction data will be collected from the online system at baseline and then continuously for the remaining 3 months of the study (participants typically shop monthly). Surveys and objective biomarkers will be collected at baseline and three-months.

Eligibility Criteria:
Inclusion Criteria:

* ≥18 years old
* primary grocery shopper for the family
* a regular in-person client at the food pantry (i.e., shops at pantry ≥ 1 per month)
* able to use the web-based touchscreen ordering system
* able to use a blood pressure cuff and scale provided to them for taking blood pressure and weight
* able to come outside their home for 5 minutes for the Veggie Meter measurement

Exclusion Criteria:

* \<18 years old
* not the primary grocery shopper for the family
* not a regular client at the food pantry (i.e., shops at pantry \< 1 per month)
* not able to use the web-based touchscreen ordering system
* not able to use a blood pressure cuff and scale provided to them for taking blood pressure and weight
* not able to come outside their home for 5 minutes for the Veggie Meter measurement
Antidepressant Therapy for Bipolar II Major Depression

This study examines the relative safety and benefit of antidepressant therapy (versus recommended mood stabilizer therapy)of bipolar type II major depressive episode. We hypothesize that antidepressant therapy will be superior to mood stabilizer therapy with little or no difference in treatment emergent manic symptoms.

Bipolar type II (BP II) major depressive episode (MDE), affects 2.5% of the US adult population and results in an estimated healthcare cost of $40 billion annually. BP II disorder is a distinct clinical entity that differs from BP I disorder, and is characterized by a preponderance of MDEs that result in particularly high morbidity and mortality rates. The treatment of BP II MDE remains a challenge for clinicians. Concerns over antidepressant drug (AD) induced manic switch episodes have led current practice guidelines to recommend treating BP II MDE with mood stabilizer (MS) monotherapy and to avoid AD monotherapy. To date, there are no controlled clinical trials to test the validity of these empirical guidelines. Results from our preliminary BP II MDE studies have shown that fluoxetine monotherapy may be safe and effective initial treatment of BP II MDE with a low manic switch rate. Based upon these observations, we now ask (Specific aim #1): "What is the relative safety and efficacy of initial AD monotherapy vs. MS monotherapy of BP II MDE?" and "What is the relative manic switch rate of initial AD vs. MS monotherapy of BP II MDE?" To answer these questions, patients with BP II MDE will be treated in a 12-week, randomized, parallel group comparison of venlafaxine monotherapy vs. lithium monotherapy. We hypothesize that AD monotherapy will have superior efficacy vs. MS monotherapy, and that there will be a similar manic switch rate among both treatment conditions. If our hypotheses are correct, we believe that these results may have an important public health impact on the current practice guidelines for treating BP II MDE.

Eligibility Criteria:
Inclusion Criteria:

* men and women (all races and ethnicity) greater than or equal to18 years of age,
* DSM IV diagnosis of BP II disorder,
* Current DSM IV MDE,
* HAM-D17 score greater than or equal to 16,
* Drug free from prior psychotropic medication greater than or equal to 7 days (2 weeks for MAOIs)

Exclusion Criteria:

* History of mania,
* Other primary DSM IV Axis I diagnosis,
* Alcohol or drug dependence within 3 months,
* History of nonresponse to Effexor-XR or lithium in the present MDE,
* History of allergic reaction to Effexor-XR or lithium,
* Medical contraindications to treatment with Effexor-XR or lithium,
* Unstable medical condition,
* Pregnant or breast-feeding women,
* Women of child-bearing potential not using a medically approved form of contraception,
* Actively suicidal or requiring hospitalization,
* Requiring concurrent antidepressant, neuroleptic or mood stabilizer therapy,
* Prior investigational study within 4 weeks of starting active therapy.
A Mother's Role in Delaying Onset of Sexual Activity in Her Children

The goal of this study is to enhance the mother's role in promoting avoidance of sexual risks and problem behaviors in 6- to 12-year-old children. Consenting mothers will attend a 10-session program designed to enhance the quality of mother-child communication, identify sexual risks, and increase parental monitoring and self-efficacy.

This study will identify personal, parental, peer, and community factors that predispose children ages 6 to 12 to early initiation of sexual behavior or that foster resilience to sexual risk taking. The study will then evaluate an intervention designed to enhance resilience factors and reduce risk factors among 6- to 12-year-old children. The study will focus on the mother's role in promoting resilience to sexual risk taking.

During the first phase of the study, 300 children and their mothers will be asked to complete a one-time interview that includes an assessment of risk and resilience factors. Information from the interviews will be used to modify an intervention currently being used in another study of parent-adolescent pairs. The modified intervention will then be tested to determine the efficacy of the intervention in reducing risk and enhancing resilience among children in this age group.

In the second phase of the study, 296 children and their mothers will be randomized to either the intervention or control group. All mothers will complete a baseline interview. Mothers in the intervention group will attend 10 group sessions that include short presentations, discussions, media presentations (videotapes), and interactive exercises, including self-assessments, role plays, and games. The group sessions include content and skill development related to parenting, communication, sexuality, peer pressure, and school involvement. Mothers in the control group receive written information on diet and physical activity. The written materials are presented in a self-help format to increase physical activity; a cookbook contains low fat recipes designed especially for African American men and women living in the Atlanta, GA, area.

All participants complete follow-up interviews at 6 and 12 months after the baseline interview. Primary outcomes for mothers include measures of resilience and communication related to sexual issues. For children, outcomes include measures related to possible sexual situations.

Eligibility Criteria:
Inclusion Criteria

* Member of a participating community-based organization
* Child 6 to 12 years of age and biological mother/legal guardian
* Ability to read and comprehend English
* Willing to participate
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Chinese participants with type 2 diabetes mellitus who are on a stable dose of basal insulin. Side effects and tolerability will be documented. Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels. The study will last up to 18 weeks and may include 18 visits for each participant.


Eligibility Criteria:
Inclusion Criteria:

* Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) and treated with basal insulin and up to one non-insulin anti-hyperglycemic medication.
* Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
* Have received a stable daily dose of basal insulin at screening
* Have hemoglobin A1c (HbA1c) greater than or equal to (≥)6.5 percent (%) and less than or equal to (≤)10.0% at screening
* Native Chinese participant who has both parents and all 4 grandparents of Chinese origin.

Exclusion Criteria:

* Have a diagnosis of type 1 diabetes mellitus or latent autoimmune diabetes
* Have a history of ketoacidosis or hyperosmolar state/coma episode or severe hypoglycemia or hypoglycemia unawareness in the 6 months prior to screening
* Are receiving insulin other than once daily basal insulin
* Have any active infectious or serious disease or major organs insufficiency
* Women who are pregnant or lactating
The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea

Ayurved Siriraj Prasaplai is a Thai traditional herbal drug for pain treatment. Mostly it was used for antipain during menstruation or dysmenorrhea. This drug has been described by alternative medical doctor for treatment of primary dysmenorrhea for more than 10 years and showed clinical satisfied response. From review about this agent, it does not have clinical trial to prove its efficacy. So the author produce this research to study in efficacy of Ayurved Siriraj Prasaplai.

The participants were allocated in the study by block randomization and double blind. In experiment-group was treated with Ayurved Siriraj Prasaplai and control-group was treated with placebo (non-active agent). Both of drug was made in the same appearance of capsule (size and color). The participants have to start the drug when they have menstruation after that the dosage is 2 capsules for 3 times per day (after-meal) continue to 3 days. The participant have to record pain score (minimal/maximal/mean score) and multidimensional score in daily card, side effect and satisfaction. If the participant couldn't tolerate the pain, they could break the pain with mefenamic acid. They have record number of mefenamic acid which they used too. This study evaluate in only one cycle. After complete record, the participant come back to investigator for sending the report.

Eligibility Criteria:
Inclusion Criteria:

* Woman who is diagnosed of primary dysmenorrhea.
* Woman who has regular menstruation.
* woman who has numeric rating score for pain during menstruation (dysmenorrhea) more than score 5 and continuous for 3 menstrual cycle.
* Woman who want to participate in this study.

Exclusion Criteria:

* Woman who has allergic history for herbal or other components in Ayurved Siriraj Prasaplai drug.
* Woman who has hormonal contraception.
* Woman who has other diseases which is caused of abdominal pain.
* Breast feeding woman